Cancer-Specific NF-kB Inhibition via Novel Small Molecule IT-848: Investigating IT-848 Monotherapy and Combination Therapy for Hematological Malignancy Treatment
ISEF · 2022 Translational Medical Science Third Award
Overview
Developing clinical Nuclear-factor-kappa-B ( NF-?B) inhibitors persists as an unresolved challenge due to the duality of NF-?B. NF-?B activity in T-cells exerts a protective effect by stimulating anti-tumor immunity, yet NF-?B activity in cancer cells exerts a destructive effect by promoting immunotherapy failure and drug resistance. A novel, direct NF-?B inhibitor, 9-chloro-8-(hexyloxy)-2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione (IT-848), exhibits clinical promise yet required further analysis in combination with current cancer treatments. To test the potential of IT-848 and Chimeric Antigen Receptor (CAR)-T cell combination therapy in evading NF-?B-dependent immunotherapy failure, cytotoxic T-cell and CD19-CAR-T cell cultures were treated with IT-848. Flow cytometry of cytotoxic T-cells revealed IT-848 did not impede Interleukin-2, Interferon-gamma, nor Tumor necrosis factor-alpha cytokine production, indicating IT-848 does not impair essential anti-tumor immune function. Luciferase assay and flow cytometry of CD19-CAR-T cells revealed that IT-848 does not reduce CAR-T cell anti-EL4 lymphoma cell cytotoxicity, yet diminishes Interleukin-6 production (p<0.01), thereby supporting IT-848 can attenuate immunotherapy failure without compromising anti-tumor immunity. To maximize the potential of IT-848 in preventing NF-?B-dependent drug resistance, EL4 lymphoma cells were treated with IT-848, CD19-CAR-T cells, and Histone Deacetylase Inhibitors. Triple therapy demonstrated an additive effect on minimizing EL4 lymphoma cell growth (p<0.05), supporting advantageous applications of IT-848 in combination therapies. IT-848 is a potent, clinically relevant monotherapy and combination therapy that also minimizes adverse side effects during hematological malignancy treatment.
Awards (1)
- Third Award of $1,000 $1,000
Competition history
- ISEF 2022
Resources
Related projects
ISEF · 2021
Direct Inhibition of NF-kB Subunits by 9-chloro-8-(hexyloxy)-2H-chromeno[2,3-d] pyrimidine-2,4(3H)-dione (IT-848)
ISEF · 2017
Harnessing Anti-Inflammatory and Immunomodulatory Potentials from Nature for Cancer Therapy
ISEF · 2022
Development of Novel, Selective, Orally Available Small Molecule CDK9 Inhibitors for Prostate Cancer Therapy - Mechanistic Studies
ISEF · 2024
Small Molecule Stabilization of the CARD11 G-quadruplex Represses Transcription: Developing a Therapeutic Target for Diffuse Large B-Cell Lymphoma
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair